Designed to be different:
Developing a potential best-in-class anti-OX40 treatment with features that matter to patients
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. Olevaprubart is our next-generation investigational anti-OX40 monoclonal antibody.
Olevaprubart
Olevaprubart is an extended half-life anti-OX40 monoclonal antibody in clinical development that targets and inhibits OX40 receptor signaling without depleting T cells for potential enhanced efficacy, safety, and patient convenience.
News
September 08, 2026
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
read more »August 17, 2026